Applied Clinical Trials
The perennial sponsor complaint: "Outsourcing costs too much." The perennial CRO response: "If you didn't assign so much internal resource to manage us, it would be cheaper."
The perennial sponsor complaint: "Outsourcing costs too much." The perennial CRO response: "If you didn't assign so much internal resource to manage us, it would be cheaper."
Well, it's true and both groups acknowledge it. Over 90% of sponsor and CRO respondents indicate that resources are assigned to oversee outsourced studies. While CROs and sponsors agree that oversight may be excessive, they do not agree on the consequences. In ISR's Staff Quality and Models report, 78% of CROs believe that oversight increases the amount of time necessary to complete a clinical trial compared to only 25% of sponsors. Sponsors hold what may be considered contradictory beliefs regarding their oversight of CROs. They believe their own oversight to be excessive; however many believe there are benefits too. Nearly half of the sponsor respondents indicated oversight reduces time; 53% believe it either reduces costs or has no impact on costs; and 77% believe it increases data quality.
From ISR's perspective, the size, global scope, and complexity of today's clinical trials are justification enough for a degree of oversight. Pharma's business challenge is identifying when enough is enough; the point when investing in more oversight no longer returns a better clinical trial. Service providers' business challenge is to better understand why sponsors insist on oversight, and then develop systems, training, and people to arrive at the right balance.
This is an evolving issue and having a better understanding of development outsourcing models as well as sponsor and service provider oversight rationale are important first steps to increasing trial efficiency and lowering industry clinical development spending. Achieving the right oversight balance can have profound effects on both individual development programs and companies.
—Industry Standard Research, www.ISRreports.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.